Access cutting-edge ocular hypertension treatment through this clinical trial at a research site in Silver Spring. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Silver Spring location
Preparing your pre-screening questions…
Access ocular hypertension specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related ocular hypertension treatment provided free
Check if you qualify for this ocular hypertension clinical trial in Silver Spring, MD
No-Cost Study Care
Local to Silver Spring
Convenient for MD residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The goal of this clinical trial is to compare participants treated with latanoprost to those treated with Rocklatan (netarsudil/latanoprost) to determine whether the addition of netarsudil results in greater improvements in episcleral venous blood flow in adults with glaucoma or ocular hypertension. Episcleral venous blood flow will be measured using erythrocyte-mediated angiography (EMA) and laser speckle contrast imaging (LSCI). The main questions this study aims to answer are: * Does Rocklatan produce greater increases in episcleral venous blood flow than latanoprost alone? * Can EMA and LSCI reliably detect changes in episcleral venous blood flow following treatment with these medications? Participants will: * Be randomized to receive either latanoprost or Rocklatan * Undergo imaging of the episcleral veins using EMA and LSCI before, during, and after treatment, and * Complete study visits that include standard ophthalmic examinations and intraocular pressure measurements. Hypothesis: The investigators hypothesize that latanoprost, which primarily increases uveoscleral outflow, will not significantly affect the distal episcleral circulation. In contrast, Rocklatan, through its netarsudil component, is expected to produce measurable increases in episcleral venous flow.
Sponsor: University of Maryland, Baltimore
Yes, this clinical trial (NCT04401982) has an active research site in Silver Spring, MD that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for ocular hypertension treatment options in Silver Spring, MD, this clinical trial (NCT04401982) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Silver Spring research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ocular hypertension specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all ocular hypertension clinical trials near you to find additional studies recruiting in your area.
See all hypertension clinical trials recruiting in Silver Spring — not just this study.
Browse Hypertension Trials in Silver Spring →